Plasma profile and urine excretion of amino acids in children with celiac disease on gluten-free diet after oligofructose-enriched inulin intervention: results of a randomised placebo-controlled pilot study.
Study Goal
The researchers aimed to determine the impact of oligofructose-enriched inulin (Synergy 1) as a gluten-free diet supplement on plasma and urine amino acid concentrations in children with celiac disease.
Results Summary
The study found that Synergy 1 supplementation increased plasma concentrations of several amino acids and altered urinary excretion patterns, suggesting improved absorption or metabolism. The Gln:Glu ratio in urine increased in both groups, indicating potential benefits for intestinal health.
Population
Children with celiac disease (N=34)
Effective Dosage
10 g/day of Synergy 1 or placebo (maltodextrin)
Duration
3 months
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | plasma concentrations of Gln | children with celiac disease (CD) | - | increased significantly | #1 |
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | urinary excretion of Asn | children with celiac disease (CD) | - | increased significantly | #2 |
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | urinary excretion of Lys | children with celiac disease (CD) | - | increased significantly | #3 |
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | urinary excretion of Aaa | children with celiac disease (CD) | - | increased significantly | #4 |
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | Gln:Glu ratio in urine | children with celiac disease (CD) | - | increased | #5 |
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | intestinal condition and permeability | - | - | could improve | #6 |
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | overall AAs metabolism | CD children | - | influences beneficially | #7 |
placebo (maltodextrin) administered for 3 months as a gluten-free diet (GFD) supplement | increase | plasma concentrations of Ala, Pro, Asn, Glu, Tyr, Lys, His, Orn | children with celiac disease (CD) | - | increased significantly | #8 |
placebo (maltodextrin) administered for 3 months as a gluten-free diet (GFD) supplement | decrease | urinary excretion of Asp | children with celiac disease (CD) | - | decreased | #9 |
placebo (maltodextrin) administered for 3 months as a gluten-free diet (GFD) supplement | decrease | urinary excretion of Met | children with celiac disease (CD) | - | decreased | #10 |
placebo (maltodextrin) administered for 3 months as a gluten-free diet (GFD) supplement | increase | Gln:Glu ratio in urine | children with celiac disease (CD) | - | increased | #11 |
oligofructose-enriched inulin (Synergy 1) administered for 3 months as a gluten-free diet (GFD) supplement | increase | plasma concentrations of Ala, Pro, Asn, Glu, Tyr, Lys, His, Orn | children with celiac disease (CD) | - | increased significantly | #12 |
The circulating amino acid (AAs) concentrations are indicators of dietary protein intake and metabolic status. In celiac disease (CD), the AA imbalance is frequently observed. Prebiotics are found to alleviate nutrient deficiencies. Therefore, the aim of this study was to analyse the impact of oligrofructose-enriched inulin (Synergy 1), administered for 3 months as a gluten-free diet (GFD) supplement to children with CD, on the plasma and urine concentrations of AAs. CD children (N = 34) were randomised into two groups, receiving Synergy 1 (10 g/day) or placebo (maltodextrin) for 3 months. The AA profile and concentration was determined in plasma and urine before and after the dietary intervention by gas chromatography. 22 and 28 AAs were determined in plasma and urine samples, respectively. After the intervention, the plasma concentrations of several AAs (Ala, Pro, Asn, Glu, Tyr, Lys, His, Orn) increased significantly in both experimental groups, while Gln increased only in the Synergy 1 group. The urinary excretion of Asn, Lys and Aaa increased significantly in the Synergy 1 group, and the excretion of Asp and Met decreased (p < 0.05) in the placebo group. The Gln:Glu ratio in urine increased in both groups after the intervention. An increased urinary excretion of AAs observed in Synergy 1 group with a simultaneous increase in the content of circulating AAs could be attributed to higher absorption or intensified metabolism of AAs, and on the other hand further healing of the intestinal mucosa being the result of continuous treatment with GFD. Moreover, the observed changes in Glu concentration suggest that oligofructose-enriched inulin could improve the intestinal condition and permeability. To conclude, a prebiotic-supplemented GFD influences beneficially the overall AAs metabolism in CD children; however, further prospective cohort studies are needed to confirm the results obtained.